REG - Morgan Stanley Takeda Pharma.Co.Ltd - Form 8.5 (EPT/NON-RI) - TAKEDA PHARMACEUTICAL
RNS Number : 2661KMorgan Stanley12 December 2018
FORM 8.5 (EPT/NON-RI)
PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY AN
EXEMPT PRINCIPAL TRADER WITHOUT RECOGNISED INTERMEDIARY ("RI") STATUS (OR WHERE RI STATUS IS NOT APPLICABLE)
Rule 8.5 of the Takeover Code (the "Code")
1. KEY INFORMATION
(a) Name of exempt principal trader:
Morgan Stanley MUFG Securities Co., Ltd.
(b) Name of offeror/offeree in relation to whose relevant securities this form relates:
Use a separate form for each offeror/offeree
Takeda Pharmaceutical Company Limited
(c) Name of the party to the offer with which exempt principal trader is connected:
Shire plc
(d) Date position held/dealing undertaken:
For an opening position disclosure, state the latest practicable date prior to the disclosure
11 DECEMBER 2018
(e) In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to the offer?
If it is a cash offer or possible cash offer, state "N/A"
YES - Shire plc
2. POSITIONS OF THE EXEMPT PRINCIPAL TRADER
If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.
(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)
Class of relevant security:
Ordinary
Interests
Short positions
Number
%
Number
%
(1) Relevant securities owned and/or controlled:
12,915,391
1.65
32,360,824
4.13
(2) Cash-settled derivatives:
31,764,207
4.05
12,002,059
1.53
(3) Stock-settled derivatives (including options) and agreements to purchase/sell:
315,000
0.04
315,000
0.04
TOTAL:
44,994,598
5.74
44,677,883
5.70
All interests and all short positions should be disclosed.
Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).
(b) Rights to subscribe for new securities (including directors' and other employee options)
Class of relevant security in relation to which subscription right exists:
N/A
Details, including nature of the rights concerned and relevant percentages:
N/A
3. DEALINGS (IF ANY) BY THE EXEMPT PRINCIPAL TRADER
Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.
The currency of all prices and other monetary amounts should be stated.
(a) Purchases and sales
Class of relevant security
Purchases/sales
Total number of securities
Highest price per unit paid/received
Lowest price per unit paid/received
Ordinary
PURCHASES
3,826,021
4,119.2272 JPY
3,679.0000 JPY
Ordinary
SALES
4,211,012
4,119.2272 JPY
3,679.0000 JPY
(b) Cash-settled derivative transactions
Class of relevant security
Product description
e.g. CFD
Nature of dealing
e.g. opening/closing a long/short position, increasing/reducing a long/short position
Number of reference securities
Price per unit
Ordinary
CFD
SHORT
36300
3714.2561 JPY
Ordinary
CFD
SHORT
6500
3710.5538 JPY
Ordinary
CFD
SHORT
200
3692.0000 JPY
Ordinary
CFD
LONG
200
3702.0000 JPY
Ordinary
CFD
LONG
400000
3771.0000 JPY
Ordinary
CFD
SHORT
2700
3692.0000 JPY
Ordinary
CFD
LONG
2700
3739.0000 JPY
Ordinary
CFD
LONG
600
3726.3333 JPY
Ordinary
CFD
LONG
523600
3724.3275 JPY
Ordinary
CFD
SHORT
13800
3702.7101 JPY
Ordinary
CFD
SHORT
100
3745.0000 JPY
Ordinary
CFD
SHORT
2200
3698.7727 JPY
Ordinary
CFD
LONG
30000
3739.0000 JPY
Ordinary
CFD
SHORT
38600
3695.3082 JPY
Ordinary
CFD
LONG
9300
3699.6559 JPY
Ordinary
CFD
SHORT
209700
3717.9007 JPY
Ordinary
CFD
SHORT
624288
3692.0000 JPY
Ordinary
CFD
LONG
124500
3843.4020 JPY
Ordinary
CFD
SHORT
124300
3840.4329 JPY
Ordinary
CFD
SHORT
100000
3874.5056 JPY
Ordinary
CFD
LONG
135941
3888.6111 JPY
Ordinary
CFD
LONG
189510
3790.1298 JPY
Ordinary
CFD
SHORT
222450
3965.6046 JPY
Ordinary
CFD
SHORT
5700
3699.7543 JPY
(c) Stock-settled derivative transactions (including options)
(i) Writing, selling, purchasing or varying
Class of relevant security
Product description e.g. call option
Writing, purchasing, selling, varying etc.
Number of securities to which option relates
Exercise price per unit
Type e.g. American, European etc.
Expiry date
Option money paid/ received per unit
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
(ii) Exercise
Class of relevant security
Product description
e.g. call option
Exercising/ exercised against
Number of securities
Exercise price per unit
N/A
N/A
N/A
N/A
N/A
(d) Other dealings (including subscribing for new securities)
Class of relevant security
Nature of dealing
e.g. subscription, conversion
Details
Price per unit (if applicable)
N/A
N/A
N/A
N/A
4. OTHER INFORMATION
(a) Indemnity and other dealing arrangements
Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:
Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"
None
(b) Agreements, arrangements or understandings relating to options or derivatives
Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:
(i) the voting rights of any relevant securities under any option; or
(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:
If there are no such agreements, arrangements or understandings, state "none"
None
(c) Attachments
Is a Supplemental Form 8 (Open Positions) attached?
YES
Date of disclosure:
12 DECEMBER 2018
Contact name:
Craig Horsley
Telephone number:
+44(141) 245 7736
Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk. The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.
The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk
SUPPLEMENTAL FORM 8 (OPEN POSITIONS)
DETAILS OF OPEN OPTION AND DERIVATIVE POSITIONS, AGREEMENTS TO PURCHASE OR SELL ETC.
Note 5(i) on Rule 8 of the Takeover Code (the "Code")
4. KEY INFORMATION
Identity of person whose open positions are being disclosed:
Morgan Stanley MUFG Securities Co., Ltd.
Name of offeror/offeree in relation to whose relevant securities the disclosure relates:
Takeda Pharmaceutical Company Limited
2. STOCK-SETTLED DERIVATIVES (INCLUDING OPTIONS)
Class of relevant security
Product Description e.g call option
Written or Purchased
Number of Securities to which option or derivative relates
Exercise Price Per Unit (USD)
Type
Expiry Date
Ordinary
PUT
PURCHASED
125,000
4507.0000 JPY
European
13/12/2019
Ordinary
CALL
PURCHASED
125,000
4507.0000 JPY
European
13/12/2019
Ordinary
PUT
PURCHASED
60,000
4596.0000 JPY
European
14/06/2019
Ordinary
CALL
PURCHASED
60,000
4596.0000 JPY
European
14/06/2019
Ordinary
PUT
PURCHASED
65,000
4414.0000 JPY
European
14/06/2019
Ordinary
CALL
PURCHASED
65,000
4414.0000 JPY
European
14/06/2019
Ordinary
PUT
PURCHASED
65,000
4414.0000 JPY
European
13/12/2019
Ordinary
CALL
PURCHASED
65,000
4414.0000 JPY
European
13/12/2019
3. AGREEMENTS TO PURCHASE OR SELL ETC.
Full details should be given so that the nature of the interest or position can be fully understood:
It is not necessary to provide details on a Supplemental Form (Open Positions) with regard to contracts for differences ("CFDs") or spread bets.
The currency of all prices and other monetary amounts should be stated.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.ENDFEOEAEAAFSXPFFF
Recent news on Takeda Pharmaceutical Co
See all newsREG - Malin Corp PLC - Malin Announces 2021 Full Year Results
AnnouncementREG - Takeda Pharma.Co.Ltd Shire plc - Confirmation of post-offer intention statements
AnnouncementREG - Morgan Stanley&CoLLC Takeda Pharma.Co.Ltd - Form 8.5 (EPT/RI) - Replacement of Takeda
AnnouncementREG - Takeda Pharma.Co.Ltd Shire plc - Statement re Applicable Exchange Rate
AnnouncementREG - Morgan Stanley Takeda Pharma.Co.Ltd - Form 8.5 (EPT/NON-RI) - Replacement of Takeda
Announcement